📰 Peginterferon Lambda News
Page 3 - Peginterferon Lambda News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Peginterferon Lambda. Real-time updates on events, politics, business and more.
January 6, 2022
/PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies...
December 21, 2021
/PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies...
December 21, 2021
/PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies...
December 16, 2021
Eiger has received a recommendation from the DSMB to continue the Phase III TOGETHER clinical trial of Peginterferon Lambda without changes.
November 4, 2021
/PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies...
November 3, 2021
GuruFocus Article or News written by PRNewswire and the topic is about:
November 2, 2021
/PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of...
November 2, 2021
Press release content from PR Newswire. The AP news staff was not involved in its creation.
May 4, 2021
Eiger to add Peginterferon Lambda to Covid-19 trial in Brazil 04 May 2021 (Last Updated May 4th, 2021 12:09) Eiger BioPharmaceuticals has said that its investigational agent, Peginterferon Lambda, will be added to the Phase III TOGETHER platform study of Covid-19 outpatients in Brazil. Share Article The study is enrolling Covid-19 patients at 11 sites in Brazil. Credit: Wilfried Pohnke from Pixabay. Eiger BioPharmaceuticals has said that its inv...
May 3, 2021
Share this article Share this article PALO ALTO, Calif., May 3, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that Peginterferon Lambda (Lambda) will be added to the ongoing, multi-center, Phase 3 TOGETHER platform study in outpatients with COVID-19. TOGETHER is an ongoing, multi-center, investigator...